$181.7M in SYK Stock Sold in Two Days by Ronda Stryker After Earnings Guidance
Form 4 filings show Ronda E. Stryker sold about $181.7M of Stryker shares on February 4-5, 2026, following the company's latest earnings and guidance cycle.
Ronda E. Stryker disclosed a heavy two-day sell window in SYK: roughly $181.7M sold across February 4-5, 2026 (about 500,000 shares total).
Transaction Breakdown
| Date | Action | Shares | Estimated Value |
|---|---|---|---|
| 2026-02-04 | S in SYK | 250,000 | ~$90.73M |
| 2026-02-05 | S in SYK | 250,000 | ~$90.99M |
The size is large, but the pattern is staged execution over adjacent sessions, which often points to programmatic liquidity management instead of a one-shot panic exit.
External Context: Post-Earnings Setup
Stryker's investor release for fourth-quarter and full-year 2025 results emphasized continued sales growth and 2026 planning. MedTech coverage also focused on procedure and segment momentum rather than a demand collapse backdrop.
Sources: Stryker investor release, MedTech Dive.
Institutional Holder Backdrop
SYK remains widely held by large institutions including Vanguard, BlackRock, State Street, JPMorgan, Banque Transatlantique SA, and Rehmann Capital Advisory Group.
Key Facts
| Insider | Ronda E. Stryker |
|---|---|
| Ticker | SYK |
| Sell window | 2026-02-04 to 2026-02-05 |
| Total sold shares (window) | 500,000 |
| Total estimated value | ~$181.7M |
What to Watch
- SYK follow-through after the filing window: relative price resilience would support a liquidity-event interpretation.
- Insider cadence: repeated block windows in coming months would be more meaningful than one two-day sequence.
- 13F positioning from Vanguard, BlackRock, and State Street: large reductions would confirm broader institutional de-risking.
Related Research
Explore all researchVictory Capital kept mega-cap tech on top in Q4 2025, but the sharper signal was in the secondary moves: large increases in Netflix, Constellation Energy, TSMC and new positions like IQVIA. The next filing will show whether that diversification continues.
Apr 17, 2026
Raymond James used Q4 2025 to keep broad ETF exposure high through VOO, AGG, SPY and IEFA while also adding to sector sleeves such as XLK and XLE. The next filing will show whether that balanced ETF-heavy structure remains the preferred setup.
Apr 17, 2026
Principal’s Q4 2025 filing looked slightly weaker on headline AUM, but the internal rotation was more revealing: Brookfield became a top-ten position, Netflix surged, and the fund cut back in parts of real estate. The next filing will show whether that shift keeps going.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
Janus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
Apr 17, 2026